iShares Neuroscience and Healthcare ETF
$33.88−1.85 (−5.19%)
- Expense ratio
- 0.47%
- Fund size
- $7M
- 1Y return
- +37.6%
- Yield · Last 12 months
- 0.90%
- Holdings
- 68
- Volume · 30D
- 0M sh
- NAV per share
- $35.32
- 52W range
The ETF.net IBRN Grade
Score 45 of 100 sits in the C band. Bands: A ≥ 70, B ≥ 55, C ≥ 40, D ≥ 25, F < 25; the scale skips E.
Cost
What you pay to own it — the expense ratio plus trading frictions, ranked within its category.BScore 56Category rankMission
How faithfully it does the job it claims — tracking its mandate or index with minimal slippage.Not scoredRisk
How violently it can move — volatility, drawdown depth, and downside capture versus its category.DScore 32Category rankTradability
How cheaply and easily you can get in and out — liquidity, spread, and premium/discount stability.DScore 28Category rankHoldings
What it actually owns — the quality, breadth, and concentration of the underlying portfolio.BScore 66Category rankDurability
Whether it will still be here — the fund’s assets, age, flows, and issuer staying power.DScore 31Category rank
Our read on IBRN
CA healthcare fund with one obsession: the brain. IBRN tracks a global index of roughly 70 drugmakers and device companies working on neurological disease, a slice most sector funds bury inside hundreds of names.
The fund seeks to track an index of global companies advancing research and treatment of neurological disorders, providing focused exposure to healthcare innovation related to brain health.
Why people hold it
- A rare single-theme cut of healthcare: brain-disease biopharma and medical devices held together, sourced globally rather than US-only.ishares.com
- At 0.47%, it undercuts the median expense ratio of its broad healthcare peer group, unusual for a narrow theme fund.
- Rules-based, not a stock picker: it follows a published NYSE FactSet neuro index, so the exposure you own is defined in advance.ishares.com
Worth knowing
- Small asset base and thin trading. Spreads can run wider than on the sector's heavyweights, and that cost lands on the buyer.
- 0.47% is several times what plain broad healthcare index funds like VHT and XLV charge. The theme is what you're paying for.
- Roughly 70 names in one research niche, live since 2022. Trial results at a few companies can swing it more than a whole-sector fund.
IBRN Holdings
- Stocks
- 68
- 42%
- EWTX
Sectors
- Health Care100.0%
Geography
- United States72.37%
- Ireland4.82%
- Netherlands4.50%
- Canada4.47%
- South Korea2.52%
- Sweden2.29%
- Denmark1.88%
- Australia1.71%
- 5.43%
Developed 85% · Emerging 15%
IBRN Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
Returns run to the Sep 22, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | IBRN |
|---|---|
| Year to date | +10.4% |
| 1 month | −10.0% |
| 3 months | −2.7% |
| 1 year | +37.6% |
| 3 years | +19.9% |
| 5 years | — |
| 10 years | — |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | IBRN |
|---|---|---|
| 2026 YTD | +10.4% | |
| 2025 | +28.5% | |
| 2024 | −2.8% | |
| 2023 | +0.9% | |
| 2022 | +5.8% |
IBRN in the news
ETF.net Research hasn’t filed on IBRN yet — coverage lands here as it’s written.
IBRN Dividends
- 0.90%
- $0.32
- $0.32 per share
- Annual
Distribution history
| Ex-date | Pay date | Amount per share |
|---|---|---|
| Dec 16, 2025 | Dec 19, 2025 | $0.32 |
| Dec 17, 2024 | Dec 20, 2024 | $0.10 |
| Dec 20, 2023 | Dec 27, 2023 | $0.0063 |
| Jun 7, 2023 | Jun 13, 2023 | $0.0082 |
IBRN Risk
- 23.2%
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- 0.69
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- −35.4%
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 0.87
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
IBRN Cost
- The middle half of Biotech & Genomics funds
- Median 0.47%
6 of the 15 Biotech & Genomics funds charge less.